| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 154.4 | 134.3 |
| Gross profit | 119.3 | 101.3 |
| Profit before tax | 4.0 | -0.1 |
| Net income | 4.1 | -0.3 |
| EPS (diluted, $ a share) | $0.08 | $-0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +15.0% |
|---|---|
| Gross margin | 77.3% |
| Operating margin | 2.8% |
10-Q filed with the SEC, NASDAQ: ATRC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
AtriCure, Inc.: key numbers
- Share price
- $55.31Close, Nov 16
- Market cap
- $2.82B
- Shares outstanding
- 50.92MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from AtriCure, Inc.
All →AtriCure Insider B. Kristine Johnson Sells $143K of Stock
B. Kristine Johnson sold 2,452 shares of AtriCure, Inc. at $58.48 a share, worth $143K in total on Nov 6, 2026. Shares held after the trade: 53,502 (-4.4%).
- Value
- $143K
- Shares
- 2,452
- Price
- $58.48
- Holding change
- -4.4%
- Trade date
- Nov 6, 2026
AtriCure Chief Technical Officer Salvatore Privitera Sells $546K of Stock
Salvatore Privitera, Chief Technical Officer, sold 8,404 shares of AtriCure, Inc. at $65.00 a share, worth $546K in total on Nov 4, 2026. Shares held after the trade: 134,341 (-5.9%).
- Value
- $546K
- Shares
- 8,404
- Price
- $65.00
- Role
- Chief Technical Officer
- Holding change
- -5.9%
- Trade date
- Nov 4, 2026
AtriCure Financial Results
AtriCure reported third quarter 2026 worldwide revenue of $154.5 million, a 15% year-over-year increase driven by strong U.S. sales in post-operative pain management and appendage management. The company achieved profitability expansion with net income of $4.1 million and adjusted EBITDA of $26.8 million, while raising its full-year 2026 revenue guidance to a range of $606 million to $610 million.
- Term
- Q3 2026
“Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution. Adoption of our innovative technologies is driving strong growth and expanding profitability, while the rapid progress of our BoxX-NoAF clinical trial reinforces our confidence in the opportunities ahead.”
Michael Carrel, President and Chief Executive Officer
AtriCure Chief Technical Officer Salvatore Privitera Sells $271K of Stock
Salvatore Privitera, Chief Technical Officer, sold 4,519 shares of AtriCure, Inc. at $60.00 a share, worth $271K in total on Sep 23, 2026. Shares held after the trade: 142,745 (-3.1%).
- Value
- $271K
- Shares
- 4,519
- Price
- $60.00
- Role
- Chief Technical Officer
- Holding change
- -3.1%
- Trade date
- Sep 23, 2026